Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany

Clinical research is a central link in the development chain of new treatment methods; scientifically, it belongs between basic science and health services research. It spans from the first application of a new substance or device in humans to the main proofs of its efficacy and safety. Economically...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen Fortbildung und Qualität im Gesundheitswesen, 2010, Vol.104 (10), p.738-743
Hauptverfasser: Vollmar, Horst Christian, Georgieff, Peter, Bührlen, Bernhard
Format: Artikel
Sprache:ger
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 743
container_issue 10
container_start_page 738
container_title Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
container_volume 104
creator Vollmar, Horst Christian
Georgieff, Peter
Bührlen, Bernhard
description Clinical research is a central link in the development chain of new treatment methods; scientifically, it belongs between basic science and health services research. It spans from the first application of a new substance or device in humans to the main proofs of its efficacy and safety. Economically speaking, it absorbs almost half of the total expenditures for the research and development of a new drug and represents a significant factor in the labour market for researchers and study personnel. Also, through participation in clinical trials, patients gain early access to new treatment methods, while on the other hand they are placed at higher risk for undesired side effects. Politics have taken significant steps to strengthen clinical research, but the pharmaceutical industry continues to complain about competitive disadvantages. Despite internationally recognised and, to a large extent, legally codified guidelines there are still significant national differences in implementation. In addition, traditional practices in clinical research are challenged by novel, mainly biotechnological therapeutic methods for which our current knowledge base is rather limited and which therefore entail a higher risk for patients or trial participants. The following paper summarises a report for the Office of Technology Assessment at the German Federal Parliament (TAB). Based on current regulations, scientific literature and expert interviews, current challenges and solution strategies for clinical research will be analysed in terms of an international comparison.
doi_str_mv 10.1016/j.zefq.2010.10.001
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_849433882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>849433882</sourcerecordid><originalsourceid>FETCH-LOGICAL-p140t-f842819e4d0ef22c08cd4840cbe150f2bde05284739c4639a49171f56c701b2b3</originalsourceid><addsrcrecordid>eNo1kD1PwzAQhj2AaCn8AQbkjSnBX0kctqqCglSJBebIcc7UVWKndlKp_HoCtNOdTs_76PQidEdJSgnNH3fpN5h9ysjfISWEXqA5lXmWlIwWM3Qd446QnPE8u0IzRqkoBC_myC9jhBg7cAP2Blvn_EEN1rs47Vi31lmtWhwgggp6-4TjEMB9DduIlWtw74cpaVUbsfEB264P_gBn2zn1q1pD6JQ73qBLM9Fwe5oL9Pny_LF6TTbv67fVcpP0VJAhMVIwSUsQDQHDmCZSN0IKomugGTGsboBkTIqCl1rkvFSipAU1Wa4LQmtW8wV6-PdOD-1HiEPV2aihbZUDP8ZKilJwLiWbyPsTOdYdNFUfbKfCsTp3xH8ATp9prQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>849433882</pqid></control><display><type>article</type><title>Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Vollmar, Horst Christian ; Georgieff, Peter ; Bührlen, Bernhard</creator><creatorcontrib>Vollmar, Horst Christian ; Georgieff, Peter ; Bührlen, Bernhard</creatorcontrib><description>Clinical research is a central link in the development chain of new treatment methods; scientifically, it belongs between basic science and health services research. It spans from the first application of a new substance or device in humans to the main proofs of its efficacy and safety. Economically speaking, it absorbs almost half of the total expenditures for the research and development of a new drug and represents a significant factor in the labour market for researchers and study personnel. Also, through participation in clinical trials, patients gain early access to new treatment methods, while on the other hand they are placed at higher risk for undesired side effects. Politics have taken significant steps to strengthen clinical research, but the pharmaceutical industry continues to complain about competitive disadvantages. Despite internationally recognised and, to a large extent, legally codified guidelines there are still significant national differences in implementation. In addition, traditional practices in clinical research are challenged by novel, mainly biotechnological therapeutic methods for which our current knowledge base is rather limited and which therefore entail a higher risk for patients or trial participants. The following paper summarises a report for the Office of Technology Assessment at the German Federal Parliament (TAB). Based on current regulations, scientific literature and expert interviews, current challenges and solution strategies for clinical research will be analysed in terms of an international comparison.</description><identifier>ISSN: 1865-9217</identifier><identifier>DOI: 10.1016/j.zefq.2010.10.001</identifier><identifier>PMID: 21147437</identifier><language>ger</language><publisher>Netherlands</publisher><subject><![CDATA[Biomedical Research - legislation & jurisprudence ; Biotechnology - legislation & jurisprudence ; Clinical Trials as Topic - legislation & jurisprudence ; Cross-Cultural Comparison ; Device Approval - legislation & jurisprudence ; Diffusion of Innovation ; Drug Approval - legislation & jurisprudence ; Drug Industry - legislation & jurisprudence ; Forecasting ; Germany ; Humans ; Politics ; Technology Assessment, Biomedical - legislation & jurisprudence ; Total Quality Management - legislation & jurisprudence ; Translational Medical Research - legislation & jurisprudence]]></subject><ispartof>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2010, Vol.104 (10), p.738-743</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21147437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vollmar, Horst Christian</creatorcontrib><creatorcontrib>Georgieff, Peter</creatorcontrib><creatorcontrib>Bührlen, Bernhard</creatorcontrib><title>Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany</title><title>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen</title><addtitle>Z Evid Fortbild Qual Gesundhwes</addtitle><description>Clinical research is a central link in the development chain of new treatment methods; scientifically, it belongs between basic science and health services research. It spans from the first application of a new substance or device in humans to the main proofs of its efficacy and safety. Economically speaking, it absorbs almost half of the total expenditures for the research and development of a new drug and represents a significant factor in the labour market for researchers and study personnel. Also, through participation in clinical trials, patients gain early access to new treatment methods, while on the other hand they are placed at higher risk for undesired side effects. Politics have taken significant steps to strengthen clinical research, but the pharmaceutical industry continues to complain about competitive disadvantages. Despite internationally recognised and, to a large extent, legally codified guidelines there are still significant national differences in implementation. In addition, traditional practices in clinical research are challenged by novel, mainly biotechnological therapeutic methods for which our current knowledge base is rather limited and which therefore entail a higher risk for patients or trial participants. The following paper summarises a report for the Office of Technology Assessment at the German Federal Parliament (TAB). Based on current regulations, scientific literature and expert interviews, current challenges and solution strategies for clinical research will be analysed in terms of an international comparison.</description><subject>Biomedical Research - legislation &amp; jurisprudence</subject><subject>Biotechnology - legislation &amp; jurisprudence</subject><subject>Clinical Trials as Topic - legislation &amp; jurisprudence</subject><subject>Cross-Cultural Comparison</subject><subject>Device Approval - legislation &amp; jurisprudence</subject><subject>Diffusion of Innovation</subject><subject>Drug Approval - legislation &amp; jurisprudence</subject><subject>Drug Industry - legislation &amp; jurisprudence</subject><subject>Forecasting</subject><subject>Germany</subject><subject>Humans</subject><subject>Politics</subject><subject>Technology Assessment, Biomedical - legislation &amp; jurisprudence</subject><subject>Total Quality Management - legislation &amp; jurisprudence</subject><subject>Translational Medical Research - legislation &amp; jurisprudence</subject><issn>1865-9217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kD1PwzAQhj2AaCn8AQbkjSnBX0kctqqCglSJBebIcc7UVWKndlKp_HoCtNOdTs_76PQidEdJSgnNH3fpN5h9ysjfISWEXqA5lXmWlIwWM3Qd446QnPE8u0IzRqkoBC_myC9jhBg7cAP2Blvn_EEN1rs47Vi31lmtWhwgggp6-4TjEMB9DduIlWtw74cpaVUbsfEB264P_gBn2zn1q1pD6JQ73qBLM9Fwe5oL9Pny_LF6TTbv67fVcpP0VJAhMVIwSUsQDQHDmCZSN0IKomugGTGsboBkTIqCl1rkvFSipAU1Wa4LQmtW8wV6-PdOD-1HiEPV2aihbZUDP8ZKilJwLiWbyPsTOdYdNFUfbKfCsTp3xH8ATp9prQ</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Vollmar, Horst Christian</creator><creator>Georgieff, Peter</creator><creator>Bührlen, Bernhard</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2010</creationdate><title>Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany</title><author>Vollmar, Horst Christian ; Georgieff, Peter ; Bührlen, Bernhard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p140t-f842819e4d0ef22c08cd4840cbe150f2bde05284739c4639a49171f56c701b2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2010</creationdate><topic>Biomedical Research - legislation &amp; jurisprudence</topic><topic>Biotechnology - legislation &amp; jurisprudence</topic><topic>Clinical Trials as Topic - legislation &amp; jurisprudence</topic><topic>Cross-Cultural Comparison</topic><topic>Device Approval - legislation &amp; jurisprudence</topic><topic>Diffusion of Innovation</topic><topic>Drug Approval - legislation &amp; jurisprudence</topic><topic>Drug Industry - legislation &amp; jurisprudence</topic><topic>Forecasting</topic><topic>Germany</topic><topic>Humans</topic><topic>Politics</topic><topic>Technology Assessment, Biomedical - legislation &amp; jurisprudence</topic><topic>Total Quality Management - legislation &amp; jurisprudence</topic><topic>Translational Medical Research - legislation &amp; jurisprudence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vollmar, Horst Christian</creatorcontrib><creatorcontrib>Georgieff, Peter</creatorcontrib><creatorcontrib>Bührlen, Bernhard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vollmar, Horst Christian</au><au>Georgieff, Peter</au><au>Bührlen, Bernhard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany</atitle><jtitle>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen</jtitle><addtitle>Z Evid Fortbild Qual Gesundhwes</addtitle><date>2010</date><risdate>2010</risdate><volume>104</volume><issue>10</issue><spage>738</spage><epage>743</epage><pages>738-743</pages><issn>1865-9217</issn><abstract>Clinical research is a central link in the development chain of new treatment methods; scientifically, it belongs between basic science and health services research. It spans from the first application of a new substance or device in humans to the main proofs of its efficacy and safety. Economically speaking, it absorbs almost half of the total expenditures for the research and development of a new drug and represents a significant factor in the labour market for researchers and study personnel. Also, through participation in clinical trials, patients gain early access to new treatment methods, while on the other hand they are placed at higher risk for undesired side effects. Politics have taken significant steps to strengthen clinical research, but the pharmaceutical industry continues to complain about competitive disadvantages. Despite internationally recognised and, to a large extent, legally codified guidelines there are still significant national differences in implementation. In addition, traditional practices in clinical research are challenged by novel, mainly biotechnological therapeutic methods for which our current knowledge base is rather limited and which therefore entail a higher risk for patients or trial participants. The following paper summarises a report for the Office of Technology Assessment at the German Federal Parliament (TAB). Based on current regulations, scientific literature and expert interviews, current challenges and solution strategies for clinical research will be analysed in terms of an international comparison.</abstract><cop>Netherlands</cop><pmid>21147437</pmid><doi>10.1016/j.zefq.2010.10.001</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1865-9217
ispartof Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2010, Vol.104 (10), p.738-743
issn 1865-9217
language ger
recordid cdi_proquest_miscellaneous_849433882
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Biomedical Research - legislation & jurisprudence
Biotechnology - legislation & jurisprudence
Clinical Trials as Topic - legislation & jurisprudence
Cross-Cultural Comparison
Device Approval - legislation & jurisprudence
Diffusion of Innovation
Drug Approval - legislation & jurisprudence
Drug Industry - legislation & jurisprudence
Forecasting
Germany
Humans
Politics
Technology Assessment, Biomedical - legislation & jurisprudence
Total Quality Management - legislation & jurisprudence
Translational Medical Research - legislation & jurisprudence
title Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A46%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20innovations%20in%20clinical%20research:%20strengths%20and%20potentials%20for%20improvement%20of%20research%20in%20Germany&rft.jtitle=Zeitschrift%20fu%CC%88r%20Evidenz,%20Fortbildung%20und%20Qualita%CC%88t%20im%20Gesundheitswesen&rft.au=Vollmar,%20Horst%20Christian&rft.date=2010&rft.volume=104&rft.issue=10&rft.spage=738&rft.epage=743&rft.pages=738-743&rft.issn=1865-9217&rft_id=info:doi/10.1016/j.zefq.2010.10.001&rft_dat=%3Cproquest_pubme%3E849433882%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=849433882&rft_id=info:pmid/21147437&rfr_iscdi=true